Logo image of CRGX

CARGO THERAPEUTICS INC (CRGX) Stock Fundamental Analysis

NASDAQ:CRGX - Nasdaq - US14179K1016 - Common Stock - Currency: USD

4.49  +0.01 (+0.22%)

After market: 4.49 0 (0%)

Fundamental Rating

2

CRGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. While CRGX has a great health rating, there are worries on its profitability. CRGX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRGX has reported negative net income.
In the past year CRGX has reported a negative cash flow from operations.
CRGX Yearly Net Income VS EBIT VS OCF VS FCFCRGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of CRGX (-59.73%) is comparable to the rest of the industry.
CRGX's Return On Equity of -76.54% is in line compared to the rest of the industry. CRGX outperforms 51.72% of its industry peers.
Industry RankSector Rank
ROA -59.73%
ROE -76.54%
ROIC N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRGX Yearly ROA, ROE, ROICCRGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRGX Yearly Profit, Operating, Gross MarginsCRGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

CRGX has more shares outstanding than it did 1 year ago.
CRGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRGX Yearly Shares OutstandingCRGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
CRGX Yearly Total Debt VS Total AssetsCRGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -0.78, we must say that CRGX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.78, CRGX is in the better half of the industry, outperforming 60.62% of the companies in the same industry.
CRGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.78
ROIC/WACCN/A
WACCN/A
CRGX Yearly LT Debt VS Equity VS FCFCRGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

CRGX has a Current Ratio of 6.30. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.30, CRGX is in the better half of the industry, outperforming 62.79% of the companies in the same industry.
CRGX has a Quick Ratio of 6.30. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.
CRGX has a better Quick ratio (6.30) than 63.34% of its industry peers.
Industry RankSector Rank
Current Ratio 6.3
Quick Ratio 6.3
CRGX Yearly Current Assets VS Current LiabilitesCRGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CRGX have decreased strongly by -42.57% in the last year.
EPS 1Y (TTM)-42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CRGX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.88% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.02%
EPS Next 2Y16.23%
EPS Next 3Y9.44%
EPS Next 5Y5.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRGX Yearly Revenue VS EstimatesCRGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M
CRGX Yearly EPS VS EstimatesCRGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRGX Price Earnings VS Forward Price EarningsCRGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRGX Per share dataCRGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.23%
EPS Next 3Y9.44%

More info and screens

0

5. Dividend

5.1 Amount

CRGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARGO THERAPEUTICS INC

NASDAQ:CRGX (8/8/2025, 8:00:00 PM)

After market: 4.49 0 (0%)

4.49

+0.01 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2025-08-10
Earnings (Next)11-10 2025-11-10
Inst Owners98.83%
Inst Owner Change-2.38%
Ins Owners0.35%
Ins Owner Change11.58%
Market Cap208.87M
Analysts49.09
Price Target5.44 (21.16%)
Short Float %7.67%
Short Ratio2.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-6.83%
Max EPS beat(2)3.09%
EPS beat(4)3
Avg EPS beat(4)5.66%
Min EPS beat(4)-6.83%
Max EPS beat(4)23.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50.04%
PT rev (3m)-50.04%
EPS NQ rev (1m)7.84%
EPS NQ rev (3m)7.84%
EPS NY rev (1m)-3.69%
EPS NY rev (3m)-3.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-3.64
EYN/A
EPS(NY)-2.41
Fwd EYN/A
FCF(TTM)-3.24
FCFYN/A
OCF(TTM)-3.17
OCFYN/A
SpS0
BVpS6.07
TBVpS6.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.73%
ROE -76.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 127.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.3
Quick Ratio 6.3
Altman-Z -0.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)467.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.2%
EPS Next Y23.02%
EPS Next 2Y16.23%
EPS Next 3Y9.44%
EPS Next 5Y5.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-37.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.17%
OCF growth 3YN/A
OCF growth 5YN/A